Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study.
- Conditions
- Health OptionsStrategic Care Planning
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 400
- Registration Number
- NCT06722846
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Interactive Design of Patient-Specific Molds for Tissue Shaping
- Conditions
- Mastectomy
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT06711965
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Renal Cell Carcinoma, Clear Cell
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06708949
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06698822
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of the ApricityCare Program for Early Detection and Management of Treatment-related Adverse Events in Patients With Metastatic Cancer
- Conditions
- Metastatic Cancer
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 425
- Registration Number
- NCT06693687
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06683755
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
NCI Cervical Cancer 'Last Mile' Initiative 'Self-collection for HPV Testing to Improve Cervical Cancer Prevention
- Conditions
- HPV (Human Papillomavirus)-Associated
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 500
- Registration Number
- NCT06676150
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06672575
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06670105
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life
- Conditions
- CancerHead and Neck Cancer
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06667427
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States